Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Status:
Completed
Trial end date:
2016-10-13
Target enrollment:
Participant gender:
Summary
This is a patient pilot study testing the hypothesis that vemurafenib with the addition of
KTN3379 can restore iodine incorporation in BRAF mutant (MUT), radioiodine-refractory (RAIR)
thyroid cancer patients.